Artivion Presents Positive Real-World Data from On-X Aortic Heart Valve Low INR Study at EACTS Annual Meeting

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, recently shared promising data from its On-X Aortic Heart Valve Low INR post-market study at the 37th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Vienna, Austria. The study, presented by Professor Aung Oo from Barts Heart Centre in London, England, demonstrated the safety and efficacy of the On-X Aortic Valve with low-dose warfarin.

The study included real-world data from 510 patients who underwent On-X Aortic Valve replacement and were treated with a lower-dose warfarin regimen. The results showed a significant reduction in the composite primary endpoint of thromboembolism, valve thrombosis, and major bleeding compared to a pre-defined historic control rate. The occurrence rate of the primary endpoint was 2.31% in the study group, compared to 5.39% in the control group (p